Sunday Science by GoUnPro 2026_11_22: H2S and Desulfovibrio and Parkinson’s
Welcome to Sunday Science, where we dive into a few recent scientific articles and their translation into our modern lives. Here is your host, Brent W. Laartz, MD. All right, everyone. Welcome to Sunday Science here on November 22nd. This is the edition for hydrogen sulfide and Desulfovibrio And Parkinson's disease and neurodegenerative disease. Interesting to me. This is a very new topic for me. Even though my master's degree is in neuroscience, and my research and my thesis were in neuroscience, and I am an infectious disease physician. First of all, really interesting in this research, in that I had, you know, we all use AI to procure for us the research of the articles that we're going to be using. And interesting that number one, that there was One article that was retracted.
It was actually from Iran, and apparently there are a few studies—not more than a few studies—a few authors in Iran that were fabricating potentially their research. And the way they discovered this was some of the research was, let's say Was they started the recruitment in August, and it was a three-month trial of 12 weeks, and they published it in. They submitted it for manuscript in September. So how can you submit a manuscript in September if your study is three months long? And how could you? And then the other ways that they determined it was that they had pregnant women in one clinic in some city in Iran, and It had a certain amount of one particular disease, gestational diabetes, and they figured from that calculation that that there's no way that they could have had that many pregnant women with gestational diabetes from one clinic in one year in Iran.
So Calculating the birth rate and calculating the number of people there, and so there was some research that was procured. This article that I found was retracted and probably fabricated was from Iran, and it was cited in multiple different studies Cited in 80 to 100 different studies, and so it was cited, It was retracted, and it still showed up in web search. But when you went to the only way that I was able to figure it out was I downloaded the PDFs of the article, and it had big red retracted all over the PDF, right? So, Great that I was able to see that. Obviously, so I'm not sharing that article with you, but it was interesting to see that nonetheless.
We're going to be talking about Parkinson's disease today, and Parkinson's disease has been theorized to be either gut-first or brain-first disease. So gut-first And we know that it is an alpha-synuclein aggregation that alpha-synuclein protein aggregates, and is now then, when it aggregates, called a Lewy body. And this is the potential Gumming up the works of these neurons in the brainstem of Parkinson's disease, and then once it gets to the brainstem, it actually then goes to different areas, cortical areas, and to the gut. And so the theory that it's gut first Comes from a lot of different studies. One couple of those are basically that Parkinson's disease is has a prodrome of constipation, autonomic dysreflexia, and this is not necessarily peripheral, but REM behavior disorders and gut issues other than constipation in the gut first.
It seems like And so that's led back in 2015 to some theories that that could be the changes in the gut microbiota that could be affecting this. For various reasons, they discovered that at that time, and Then there are also so a certain portion of Parkinson's disease and other neurodegenerative disorders are brain first, and some of them are genetic, and they are genetic in potentially the genes that encode the alpha synuclein. So one would expect that isn't necessarily going to be gut first. It might be more like brain first, right? So, Then, but that's only about 10 to 15 percent of Parkinson's disease or less. And, but there are other genetic forms involved with lysosomes and clearing of the alpha synuclein.
Because if you have an abnormal alpha synuclein and you have the first thing that's going to have to happen Is you need to clear it out of the system, and or, and so some of these genetic forms are related to lysosomes and endolysosomes and whatnot. So those might be the brain first portions, right? So, or, and I have a personal friend who has a mother who had Parkinson's disease, and I remember kind of that she always had some gut things and gut issues and constipation, etc. And so, if in your 40s, 30s, 40s, 50s, you have constipation, there are various reasons this can occur. But maybe it's the neuroendocrine system in the gut that is damaged first. And then it goes to the brain, and we'll talk about that more.
All right, so all right, so here's the Desulfovibrio bacteria and Parkinson's disease. All right, so it is a. We're going to start out with the Koterba review. Okay, so the Koterba review is a really good review that just came out this last month about the sulfate-reducing bacteria hypothesis in Parkinson's disease from Desulfovibrio-derived hydrogen sulfide and The theory that low amounts of hydrogen sulfide are actually good because there is some neurosignaling that goes on in the gut and in all cells that are that is actually a good normal phenomenon, normal function of hydrogen sulfide, and we many of our own cells have hydrogen sulfide reduction capability. And then there are multiple different bacteria that can do this as well, not just Desulfovibrio.
All right, so when you have too much of hydrogen sulfide in your enterohepatic, sorry, in your entero neuroendocrine cells, potentially that could be toxic To the alpha-synuclein, and they've determined that it is now different strains of Desulfovibrio, and that these different strains, most of which do this, and a couple of which, which are environmental strains and not animal strains. Actually, do this normally in a normal function and a normal amount, but most of the strains that are obtained from animal and human and pathological samples, in other words, samples from persons with Parkinson's disease, have the capability to reduce And cause unfolding, misfolding of the alpha-synuclein protein, causing aggregation, and actually physically seeing this in the test tube. And so, and the fact that this bacteria is implicated in neurodegenerative diseases, higher, and this.
Bacteria de sulfa vibrio and the hydrogen sulfide production is in higher concentration in meat eaters, eaters of processed foods, foods that are rich in taurine, which is basically high fat and high meat, high animal product proteins, and also heme. So, and we'll talk about that in a second because basically, Heme has a lot of iron, right? And so we do know that persons with hemochromatosis, for example, have a higher rate of Parkinson's disease. This causes reactive oxygen species and free radicals, and then iron-free radicals. So the reduction of iron too, with something called the hydA gene, which encodes an iron-iron hydrogenase, iron-sulfa hydrogenase, and it's used by many anaerobic bacteria. So this is not this is a gene not just relegated to the Desulfovibrio.
But the hydA gene and its iron-iron hydrogenase causes iron to be in an Fe2+ state, which can create iron-free radicals and magnetite. Magnetite production also and presence has been associated with Parkinson's disease and neurodegenerative diseases. So potentially, now we have a bacteria that has been implicated in Parkinson's disease. It is in higher presence in meat eaters, processed foods, foods rich in taurine, heme Molecules, which if you're going to eat red meat, that is going to be where you're going to get your heme in your diet and in your intestines to have this happen, and high fat diet. All right, so we're going to go over some of the interesting studies here. So this is the review by Koterba. This is a little schematic of the brain first.
Versus the gut-first Parkinson's disease model, so the brain-first, basically, potentially the origin in the disease starts in the olfactory bulb and the brain up here. And so you can see that potentially people with Parkinson's disease start out with hyposmia as one of their central issues. Then the pathway and spread from there goes to the olfactory bulb, goes down to the substantia nigra, which is then where you have your neurodegenerative disease and Parkinson's disease. There are other neurodegenerative diseases that occur in other parts of the midbrain, the pons, etc., and so the question begs to differ. Are these just different pathways of similar issues, right? So, and the propagation then goes from the brain to the gut instead of the other way around. So the prodromal stage often is RBD negative.
In other words, they are REM Behavior disorder negative, so they don't have that issue. Often, their cardiac and autonomic system is normal or near normal, and the diagnosis typically has less enteric systems at the beginning and maybe toward the end. And all models converge in the late stages, affecting the entire neural system. Okay, so on the right we have the gut first model, and the starting point appears to be in the enteric nervous system of the gut and gut microbial dysbiosis, loss of the protective bacteria, misfolding of the alpha synuclein, and actually propagating that up to the enteric nervous system via the Vagus nerve, the vagal nerve System basically takes this right up to and where does the Vagus nerve end, but in the midbrain and right where Parkinson's disease starts in the central nervous system.
And so potentially the bottom up, you've got dysbiosis first. Early symptoms are often non-motor autonomic systems. Constipation, loss of smell, and other, and also a prodromal stage with a with RBD, the REM sleep behavioral disorder. So, REM sleep behavioral disorder is a is a system where you have is a disorder where you have Different REM behaviors. So during REM sleep, acting out in the dreams, sleepwalking slash sleep talking, and you know it's usually more than just your usual sleep talking. It is major issues, right? So the prodromal stage, Cardiac and autonomic degeneration of the cardiac sympathetic nerve, so sympathetic tone, etc., and so dysreflexia, and then diagnosis often slow, silent, systemic progression before the motor onset and before the rigidity and the cogwheel and the slow pace of motor.
Output then leads from there once you get up into the cortical brain. So, all right. So, and again, ultimately, both models converging in the late stage. All right. So We're going to talk a little bit about the hydrogen sulfide pathogenesis. So here we have in the enteric cells, in the neuroendocrine cells of the gut, enteroendocrine cells, you have in the back, in the lumen of the gut, Desulfovibrio and hydrogen sulfide-producing bacteria producing these hydrogen sulfide gas levels, and that does two things. It causes intestinal barrier damage, which is why these hydrogen sulfide bacteria are associated with intestinal barrier damage. That increases the risk of ulcerative colitis and Crohn's disease And potentially now also colorectal cancer, and then all of that portion there, and all the inflammation that it will potentially lead to other issues with the body, right?
And with the we know the gut-brain axis access from there, and also the inflammation, arthritis, and other autoimmune issues. And inflammation of inflammation and aging occur from there. Okay, so then in the middle of the slide, you can see that what does this happen? What happens with this? The inhibition of cytochrome C oxidase and releases cytochrome C And poisoning of the mitochondria in these areas, causing decreased energy production, decreased tight junctions, and then also then an interaction with iron, causing iron to have iron-free radicals Fe2+, causing then induction of other free radicals and reactive oxygen species, and then causing then the misfolding of And aggregation of alpha synuclein, and then that being propagated by the Vagus nerve, and then up to the brain from there.
So you have your non-motor GI symptoms: constipation, gut dysfunction, and tremor and rigidity of the GI system. So, Reactivity of the intestinal motility. Okay, so then going on to your central nervous system and having the motor motility. Okay, so then going on from here, a brand new article, essentially We know that there are since 2015, 2019, 2021, the discovery, the new discovery of these Desulfovibrio bacteria. But there are some bacteria that are that have been found that they haven't Been able to characterize, and there are some people that don't have with Parkinson's disease that don't have the Desulfovibrio bacteria. And there is a brand new study here, basically finding three new species of Desulfovibrio that were not found before. And this is a breakthrough here because now we can basically.
Find some new bacteria that may be involved, and so this was. I thought I'd share this really simple study where they basically just characterize the study of these bacteria. So this article by Murros In frontiers in cellular and infection microbiology, basically is a PCR-based assessment of quantities of Desulfovibrio bacteria in basically 20 Parkinson's disease patients and 20 controls. They did PCR for both DSV. I'm going to call it that from now on, so I don't have to keep pronouncing Desulfovibrio And the hydA gene that we talked about before, that is associated with iron-iron hydrogenase hydrogenation, that then basically creates the iron-free radical from the hydrogen sulfide and production of the hydrogen sulfide. Okay, so it takes hydrogen, creates hydrogen sulfide.
And then from there, also takes that hydrogen sulfide and basically creates free radicals, and takes the hydrogen and two iron molecules, creates Fe two plus, donates electrons to that hydrogen sulfide, and basically then creates free radicals from there, right? So These two things they did PCR in these 20 patients. Very small study, but the Desulfovibrio is increased in 80% versus 40% of controls, and the gene is present in 100% of Parkinson's disease patients versus 65% of controls, and it is. And what they did from there was is that they characterized the quantity then of the Desulfovibrio based on Parkinson's disease patients and their severity, and there is a higher amount In each Parkinson's disease, and it's correlated with disease and constipation, and the normal controls who had constipation as a symptom, it was associated in higher amounts with those patients who had constipation.
So in these normal controls, maybe they're in a prodrome, or maybe they're early Patients of Parkinson's disease or some neurodegenerative disorder, or at least some compound of some at least enteric neuroendocrine system dysfunction. That is the reason, and maybe it's because of some of these bacteria and these and this gene. So certainly Some of these patients had no DSV bacteria and the Hyde A gene. We know that Hyde A gene is not just associated with Desulfovibrio; it can be associated with other bacteria. So maybe the amount of HydA gene Associated with constipation might be from other bacteria or from Desulfovibrio that just have not been discovered yet. Okay, so a very interesting study.
I encourage you to read this because it's it does go into and it has a good table there of the Hyde gene in each of these 20 patients in each of the control and the Parkinson's disease on The quantity in each of those patients, and then the Hyde gene, whether it's present or not, and the Hyde gene is present again in the stool of 100% of the Parkinson's disease patients in the intestinal milieu, in the microbiota, right? So, Perhaps there are other bacteria there that are in higher quantity, and it's not just the Desulfovibrio. Okay, again, there are other bacteria that produce this hydrogen sulfide gene.
And all right, so let's go to then this article by Mohammadi. And the strain-specific effects of Desulfovibrio on neurodegenerative degeneration and oxidative stress in a C. elegans Parkinson's disease model. So they there's a C. elegans, which is a worm nematode that that Had model NL5901 that expresses human alpha synuclein. So now you can see what different perturbations can cause the alpha syn aggregation, reactive oxygen species production, gene expression, and then the lifespan also of that that model. So, They were fed a few different isolates of Desulfovibrio, and two of the isolates that are from animal sources caused increased alpha-synuclein folding and aggregation, reactive oxidative species, and decreased lifespan. And another source of Desulfovibrio that was from Parkinson's disease patient did the same thing. Okay, so here's very early proof in a nematode, a simple model from a nematode, The C. elegans model, which is used a lot in Parkinson's disease research, there was one environmental Desulfovibrio strain that was actually a preferred food source.
So if the if the C. elegans. Had a choice as to which food to eat, either the Desulfovibrio in a food that was from an animal source or one that was from an environmental source, The worm actually preferred that and had Decreased aggregation, decreased reactive oxidative species, and also had a longer lifespan it chose that environmental source. When I say environmental source, I'm talking about a soil source because this bacteria is found in soil and it is found in other Environmental sources other than just animal feed. Okay, so interesting study there because now you have basically a basic science strongly showing that this is reasonable, good theory for the Propagation of alpha synuclein and causing the misfolding and aggregation and the reactive oxidative species going from there right up to then where now you have to get it from the gut to the brain and so now.
Next article was from actually from earlier in 2026.This is microbiome signature Parkinson's disease in healthy and genetic at-risk individuals. This is by Minozzi et al. And there are certain species that were associated with Parkinson's disease in higher concentrations. And there are some species that are present in lower concentrations or deficient in both the patients and also in the prodrome patients. And they came up with 16 different species. And they came up with a PDMS-16 score based on the amount of those species. The issue with this article is that some of these species associated, and some of them are Bifidobacterium longum and Bifidobacterium adolescentis and Lactocasio bacillus rhamnosus. All of the three of these bacteria, per se, are associated with number one.
They are in a lot of our probiotics that we use, and they are also thought to be protective. And we'll talk about that in a little bit in the next study. But for some reason, they're there, and so it begs to differ. Why are they there? Are they there because of some reason? One could be because of levodopa. Now, with their present and because of levodopa, they're not going to be given in patients who have the prodrome and have pre-Parkinson's disease because they're not going to be treated with levodopa. But maybe there are. They do know that there are certain Bacteria that are adept at the metabolism of dopamine and some neurotransmitters like serotonin in the gut, and so if you're feeding the gut bacteria levodopa, and there are certain ones of them that thrive on it.
They're going to be present there at more concentration, and we know that that is a possibility. Not necessarily with these 16 bacteria, but that is a theory. Or is it causative? Is the perturbation there causative? We know that these bacteria that are here actually produce good things for your intestines. So the Butyric acid and the propionic acid and the acetic acid that are good for your bacteria, the short-chain fatty acids. So they're protective of your gut. So how are they necessarily causative, or are they consequence of the constipation, et cetera? Are they bacterial overgrowth because of the constipation? Noticeably absent here, except in one of the prodromes Areas is Desulfovibrio bacteria, and what we don't know is whether they may not have had the correct primers to determine that there was Desulfovibrio bacteria here.
But there was one barely significant Desulfovibrio Bacteria present in the prodrome that I can notice, and they did not necessarily use that in their PDMS16, the score of 16 bacteria predicting the severity. This PDMS16 used the 16 bacteria that are present in higher amounts in both of the diseases. In the prodrome and the Parkinson's disease, and so this PDMS 16 they then took to determine, and it actually predicted severity of Parkinson's disease in the Parkinson's disease patients, and predicted severity of constipation as well in the prodrome patients. All right, so and obviously, if it's if it's present in of these 271 patients with Parkinson's disease and the 43 carriers of GBA1, so that's the prodrome patients where the 43 carriers of GBA1 not manifesting PD symptoms. Those were the prodrome patients.
And from 150 health control, so maybe you know certainly if they took this as a high concentration in these particular patients, of course it's going to predict severity because it's going to be present in most of those patients, and therefore May predict severity, so there's a little bit of an obvious part to this. But it is worth noting that there is a definite change in bacteria in the microbiome signature of Parkinson's disease and genetically at-risk individuals. This article by Talebzadeh is Interesting in that now we know this Desulfovibrio selective probiotic strains, sorry, selective strains, and now we can target that with probiotics, and potentially we do know now with this article That you can suppress the Desulfovibrio by giving selective probiotic and potential probiotic strains, and they found a certain set of species of eight bifidobacterium and lactobacillus species, and a couple of these, interestingly, the bifidobacterium longum and the lactobacillus plantarum that were actually present in.
Higher amounts in Parkinson's disease patients in the prior study. So, if I can basically give a probiotic to decrease bifidobacterium, sorry, decrease Desulfovibrio bacteria, and with those probiotic strains, but yet they are present in higher amounts. In the PDMS16 score, then what is actually happening there? Is it a reaction from the host to try to get rid of the Desulfovibrio bacteria or the hydrogen sulfide-producing bacteria? Another interesting study by Magistrella, again, a probiotic, Bifidobacterium animalis. They took patients who had Parkinson's disease and they gave them probiotics. We have 40 patients before and after They gave them either the four species probiotic, Bifidobacterium animus, longus, and adolescentis, and another bacteria plus maltodextrin plus fructooligosacteride, or they gave them just maltodextrin, which is a potential prebiotic. It's a maltodextrin.
And so they showed that in these Parkinson's disease patients, it decreased the motor and non-motor symptoms, decreased interferon gamma and IL-6, which is elevated in persons with Parkinson's disease, and it increased the anti-inflammatory cytokine TGF beta in these patients, and Again, decreased the motor and non-motor symptoms by giving a probiotic with these four bacteria and fructooligosaccharide and the maltodextrin. So, and both sets of patients had decrease in interferon gamma. Both sets of patients, even the maltodextrin, which One could theorize that maltodextrin is a prebiotic. It is a fibrous compound that is non-probiotic, but it is something that could increase a normal good species. And so there is actually a small decrease in interferon in those patients that were just received the placebo, which is not exactly placebo.
Okay, so but it also in the Parkinson's disease patients that were given the four species of probiotic decreased IL-6 as well, which did not happen in just the plain maltodextrin portion of the study. All right, so interesting study here. This was from earlier in two thousand twenty-six as well. Sorry, two thousand twenty-four. So this has been known for a little bit. So, um, the probiotic treatment of Parkinson's disease. If I had anybody who had any kind of neurodegenerative disorder, I would think that such a harmless. Treatment of giving different species of probiotics, trying to do all kinds of different fermented foods, yogurts, and probiotics. I would definitely try to do it, right? So all the more reason why we need this in our diet, and we need, and hence why fermented foods, and why these non-animal sources.
Of bacteria potentially are great, right? So, um, all right. So, one last one, which I actually just came across last night before coming to this, and I thought, okay, let's just throw this in there .It is interesting, just information on what the Desulfovibrio bacteria could be doing in our gut and in our central, in our peripheral nervous system, in our entero-neuro-endocrine system, and these cells, and potentially just showing that there is a little bit more than just the. Hydrogen sulfide production that there also may be the flagellin T TLR five activation, and this hence downregulating TGF beta. We just talked about that impaired immune tolerance and increasing inflammation. All right, So again, we just talked about in the last study where probiotics actually increase TGF beta.
Here we show that through toll-like receptor five activation from the flagella of this bacteria, the Desulfovibrio bacteria, it can signal in small intestinal organoids. Suggesting impaired immune tolerance induced by Desulfovibrio, and hence, therefore, potentially increasing inflammation. Okay, so increasing inflammation, increasing the intestinal damage, increasing intestinal tight junction issues, and maybe lipo polysaccharide crossing into the gut back barrier and crossing that, and then causing inflammation, sending it to the rest of the body. Okay, so potentially keep an eye on this Desulfovibrio bacteria, and we do know that there are other bacteria potentially associated with these different degenerative diseases. That also produce hydrogen sulfide, and those bacteria are Bilophila, Colinsella, Porphyromonas, and actually even potentially other bacteria. And so this last slide potentially showing the microbiota-driven alpha-synuclein.
Aggregation and potentially other effects of this alpha-synuclein and other if hydrogen sulfide and other types of purling can occur, then so the primary driver of the top right metabolic hydrogen sulfide and sulfate reduction. And the key bacterial factors are the sulfate-reducing enzyme and the lipopolysaccharide, the cellular consequence of high reactive oxygen species mitochondrial damage, accelerated intraneuronal alpha-synuclein aggregation, and there is strain specificity. So in the first one, In the first portion there, Desulfovibrio, we already talked about that ad nauseum here about patient-isolated strains, Parkinson's disease-associated Desulfovibrio, versus there are some harmless environmental strains. And then in the middle, actually, there are some curly-producing E.coli and salmonella That actually produce amyloid fibers of the curly CSGA that can also do some of this damage to alpha-synuclein and amyloid fibers that could produce other issues in the Vagus nerve and produce neurodegenerative disease.
And whether it causes Parkinson's disease or other diseases, that it remains to be seen. Okay, so cross-seeding and amyloid aggregation. We know that amyloid is bad, and so there are certain E. coli that can produce this as well. Then there is also Then the pro-inflammatory bacteria on the right, potentially just producers of lipopolysaccharide, and all of these different dysbiosis bacteria that, when you have ultra-processed foods here as well, then that can produce a leaky gut Permeability, inflammatory cytokines, gut barrier dysfunction, immune activation, and then indirect misfolding of alpha-synuclein and other inflammatory issues beyond that. Right. So here is a plain and simple, but yet complicated, because There are certain bacteria that also can produce this and are associated with disease. It's not just Desulfovibrio.
But one banks to differ, and here's the comedy portion of this, is that I'm sure that we've all had that rotten eggs passing of gas, right? And so the flatulence that is hydrosulfide. Boy, if I ever had that, boy, is that a cause for alarm? Because number one, that notification that that is happening is certainly a noxious stimulant, right? The noxious really shocks you, right? Right. So you have that. And when do you normally have that? Think to when you normally have that. It's normally when you have when you've eaten something particularly bad for you, right? And certainly we know that this these strains and this hydrogen sulfide is higher in processed meats and red meats, and potentially the reason in high fat foods.
And so you eat these high-fat foods, and if you have hydrosulfide, and if you have predilection to either the either the GBA1 gene that predilects you to developing Parkinson's disease, or other reasons, or maybe it just could affect other things. All the more reason, and when that happens, you better get some probiotics, right? So I'm not telling you to go, but probiotics. I'm talking in general, right? But it would tell me that that is a shocking and potentially reason to do something about it, right? The comedy portion to it, and it seems reasonable that if you do have that. Sulfur smelling, the rotten egg smelling thing—that there is something wrong. And it—we all know when you kind of—we all know those people that have smelly farts.
And then we all have potentially, hopefully, it's your girlfriend or actually a boyfriend. Hopefully, they have non-smelly farts. But passing of gas, if you have a non-smelly one. All the better. It means you're a little bit more healthy, right? So, all right. So that is Sunday Science. Thanks for joining us on Sunday Science. Here's the different articles, and again, they'll be in the show notes for us here. But these are the different articles we brought forth. There was a couple of more in there that that I Added about the effect of probiotic strains on Parkinson's disease, and so there's more than just the seven articles that we presented here. All right, so again, this is the Sunday Science broadcast by Go On Pro, and you can follow us here.
We're found on Go On Pro on the far right, GoOnPro.com. Okay, so you can listen on YouTube, Substack, Apple Podcasts, Spotify, and wherever you find your audio podcasts. Again, Sunday Science, we usually present slides here, so it is useful to be on the on the Video portion on YouTube. Just search @BrentWLaartzMD on TikTok, Instagram, Facebook, Threads, and Substack. It's either Brent W. Laartz MD or it's Brent.W.Laartz.MD. That's Brent.W.L A A R T Z. MD. Again, or @BrentWLaartzMD is the handle. Okay, so All right, we're on everywhere you can find us. Every place that you can get an audio podcast, you can find us. But also, again, check us out. Subscribe on Substack.
Very important there. You can see the entire transcript on Substack. You can see the entire transcript on GoOnPro.com. And then a lot of times, just the summary is on YouTube. For the show notes, but again, on Apple Podcasts and Spotify, you're going to be able to find the summary, but not the full transcript. So you can read through the transcript found there at GoOnPro.com and Substack to see what we're talking about. If you want to read this rather than Find it again. The articles are going to be there. Thanks for joining us. We're hoping to do this a little bit more frequently. We know we've been doing this only kind of about once monthly or once every three or four weeks, but we're hoping to do this almost every week.
It's difficult for me because some weekends I'm working and it's a little bit difficult to find the time to get to this. And thank you for joining me. I love that you're loving the science. And again, my recommendation to you, again, from the very beginning of this, about the retracted article. Don't just take your research on Google or whatever AI you might use, because it could come up with an article that has been retracted. And learn that this time because I always pull the PDFs of every interesting article I come by, and I know that's difficult because you have to have some access I have an institutional through my university to be able to get access to that PDF, but there are ways you can get to the Full text on the journal website.
So if you go to the journal website, you will also be able to find that it's been retracted from the journal website itself. Don't just go based on some curation of some articles in a summary, because that summary doesn't know that it's been retracted. Okay, so. And it doesn't know the quality. It doesn't know the actual articles and the what was found within the article. Okay, so again, thank you for joining me. I love that you guys are with me. I I thank you from the bottom of my heart exactly what we're doing. Thanks for joining me here. I hope you guys have the best.
Information that you can get gleaned from what I'm studying here. And again, we are almost to the end of the 52 weeks journey on Go On Pro, the podcast. We have a lot in store after 52 weeks. Also, coming up at 52 weeks, we're going to start interviewing people. And not just have this be a soliloquy. We're going to have some of the staff at GoOnPro.com and Kariba ID Publishing. We're going to have some people, different authors, and different celebrities on. Thanks for helping me to increase my reach To everyone out there who's interested in the science of longevity and not just the popular bro, gym bro type of issues that some of the people out there in this space are doing, and I go to different, I go to different.
Conferences and different scientific arenas within the space of longevity in the microbiome and microbiome space, and it does tend to attract people who are wanting to make money off you. And let me tell you, I'm not making any money off of this. My advertising, if you see advertising on this, it brings in a pittance. And brings in enough money to only basically pay for the streaming of this and the production of this. So, so I'm not in this for the money. I don't want to be a celebrity. I don't want to be a person who's going to be selling you probiotics. I'm never going to sell a probiotic on this. I may suggest probiotics. And we may get some referral fees, et cetera. Again, those are pittances.
When people get referral fees, they don't get much money from that. Okay, so what I'm never going to do is sell directly to you and hawk that kind of product. Okay, so Believe me when I say I make enough money from my day job that I can do this, and I don't have to worry about selling anything to you. And I love that about what I'm doing, and this is why I'm so passionate about it. This is why I love science. I love where things can go if we just study the science, and. This particular podcast, this particular subject, was new to me, and so I love discovering new things about the microbiome, about longevity that I can do and I can take to my life.
Some of this is directly exactly what I can do in my life that can basically, Help me in my life because what are what is a certain amount of people going to die of, and it's neurodegenerative disorders. They are increasing in the world, and what a great source of information here that I can potentially decrease my red meat, decrease my high fat compounds that I'm eating, and decrease my animal sources, increase basically non-sulfur producing diet, and go from there. So what a what a great thing, right? So thanks for joining me. I know it's again been a little bit of a long. Podcast here for the Sunday Science. Thanks for joining me. I love that you're with me. I love that we're all in the right space here.
Thanks for joining. We'll see you soon. This site and any information communicated within it are not intended as medical advice. The information herein is not intended as medical care, diagnosis, or treatment of any medical condition. No component of this content, including discussion or comments, shall be construed or implied as establishing a doctor-patient relationship. Before you translate or copy any of the information, diet, exercise, or products utilized herein, or on any social media post to your own practice, consult your own research, physician, therapist, or nutritionist for your own health. No warranties or claims are made as to the benefits or risks of any treatments, diet, exercise, or products herein. Research any treatments, diet, exercise, or products thoroughly before trying for yourself. Referral, affiliate, or advertising fees may be garnered by this site.
Koterba M, Skiba A, Kler A, Błaszczyk K, Woźny M, Stefaniak O, Nowicka J. The Sulfate-Reducing Bacteria Hypothesis in Parkinson’s Disease: From Desulfovibrio-Derived Hydrogen Sulfide to Alpha-Synuclein Aggregation. Biomedicines. 2026; 14(10):2256. https://doi.org/10.3390/biomedicines14102256
Mohammadi, K., Zhang, D. & Erik Joakim Saris, P. Strain-specific effects of Desulfovibrio on neurodegeneration and oxidative stress in a Caenorhabditis elegans PD model. npj Parkinsons Dis. 11, 236 (2025). https://doi.org/10.1038/s41531-025-01102-z
Talebzadeh S and Saris PEJ (2026) Targeted in vitro suppression of Parkinson’s disease-associated Desulfovibrio by selective probiotic and potential probiotic strains. Front. Microbiol. 17:1925465. doi: 10.3389/fmicb.2026.1925465
Barham M, Mayer MJ, Gotts K, Narbad A, Sayavedra L. Expanding the diversity of Desulfovibrio from the human gut: Desulfovibrio intestinivivus sp. nov., Desulfovibrio desulfopostgatei sp. nov. and Desulfovibrio faecalis sp. nov. Int J Syst Evol Microbiol. 2026 Sep;76(9):007296. doi: 10.1099/ijsem.0.007296. PMID: 42784212; PMCID: PMC13609909.
Menozzi, E., Ren, Y., Geiger, M. et al. Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals. Nat Med 32, 2096–2106 (2026). https://doi.org/10.1038/s41591-026-04318-5
Magistrelli, L., Contaldi, E., Visciglia, A., et al. (2024). The Impact of Probiotics on Clinical Symptoms and Peripheral Cytokines Levels in Parkinson’s Disease: Preliminary In Vivo Data. Brain Sciences, 14, 1147. https://doi.org/10.3390/brainsci14111147
Ibrahim, A., Ali, R. A. R., Manaf, M. R. A., et al. (2020). Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson’s disease: A randomised controlled trial. PLOS ONE, 15, e0244680. https://doi.org/10.1371/journal.pone.0244680
Park, J. M., Lee, S. C., Ham, C., & Kim, Y. W. (2023). Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson’s disease: a meta-analysis of randomized controlled trials. Gut Pathogens, 15. https://doi.org/10.1186/s13099-023-00536-1
Murros KE, Huynh VA, Takala TM, Saris PEJ. Desulfovibrio Bacteria Are Associated With Parkinson's Disease. Front Cell Infect Microbiol. 2021 May 3;11:652617. doi: 10.3389/fcimb.2021.652617. PMID: 34012926; PMCID: PMC8126658.
Zheng, T., Keidel, I., Omer, H. et al. Extensive genomic diversity in Desulfovibrio reveals species-specific functional traits associated with disease. Nat Commun 17, 10655 (2026). https://doi.org/10.1038/s41467-026-78314-1

Comments